HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].

Abstract : Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent Mendelian inherited disorder. It covers 6.1% of incident ESRD patients in France in 2011. Long left untreated, this disease will soon benefit from targeted therapies currently under evaluation. Several molecules have already reached the stage of clinical trials: the evaluation of mTOR inhibitors yielded deceiving results and, more recently, 2 different molecules demonstrated a slight impact on the progression of total kidney volume (TKV): tolvaptan, vasopressin receptor-V2 inhibitor and somatostatin analogues; both of these molecules acting throughout the decrease of intracellular AMPc. The purpose of this review is to briefly describe the signaling pathways involved, then to present both the published and ongoing clinical trials and the promising molecules evaluated in murine models.
Document type :
Journal articles
Complete list of metadata

Contributor : Geneviève Michel Connect in order to contact the contributor
Submitted on : Tuesday, March 10, 2015 - 3:15:47 PM
Last modification on : Monday, October 11, 2021 - 2:23:08 PM


  • HAL Id : hal-01128884, version 1
  • PUBMED : 25086476



Emilie Cornec-Le Gall, Yannick Le Meur. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].. Néphrologie et Thérapeutique, Elsevier Masson, 2014, 10 (6), pp.433-40. ⟨hal-01128884⟩



Record views